A PHASE 1 RANDOMIZED, CONTROLLED, OBSERVER-BLINDED, MULTICENTER STUDY TO EVALUATE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF AN INVESTIGATIONAL ADJUVANTED TETANUS/DIPHTHERIA/PERTUSSIS BOOSTER VACCINE (TDAP-1018) IN ACELLULAR PERTUSSIS VACCINE PRIMED HEALTHY VOLUNTEERS 18 TO 23 YEARS OF AGE

Registry ID
DV2-TDAP-02
Source registry
HEALTH_CANADA
Status
Pending
Phase
PHASE1
Study type
INTERVENTIONAL
Sponsor
DYNAVAX TECHNOLOGIES CORPORATION
Last update
2022-07-29

Conditions

View on source registry